CERO Therapeutics ISIN: US71902K4022 Forum: Aktien User: senveben

250% AH fuckkkkkkkkkk

200% krank wollte bei 0,10$ rein fuck

AH 150%

CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML

On October 14, 2025, Cero Therapeutics Holdings, Inc. filed an 8-K reporting a securities purchase agreement to raise up to $7 million through the sale of 9,750 shares of Series E convertible preferred stock.

D. Boral Capital maintains BUY rating and $30 price target

CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML

Chris Ehrlich, CEO von Cero Therapeutics, einem Biotech-Unternehmen für T-Zelltherapie, erklärte gegenüber Axios Pro, dass das Unternehmen für Lizenzvereinbarungen oder einen Verkauf offen sei, während es auf Daten zu seinem wichtigsten Produkt wartet. Zelltherapie-Unternehmen sind in den Fokus großer Pharmakonzerne geraten.

Cero Therapeutics has received a decision to grant European patent number EP4376874 titled "CHIMERIC TIM4 RECEPTORS AND USES THEREOF (FOR THE TREATMENT OF CANCER)".

$CERO - CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041

CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML) Already holds Orphan Drug Designation

CERo Therapeutics Is Maintained at Buy by D. Boral Capital

Urlaub machen nix börse